DEMENTIA WITH LEWY BODIES: CLINICAL AND PHARMACOLOGICAL MANAGEMENT STRATEGIES
DOI:
https://doi.org/10.56238/isevmjv4n6-019Keywords:
Dementia with Lewy Bodies, Acetylcholinesterase Inhibitors, linical ManagementAbstract
Dementia with Lewy bodies (DLB) is a progressive neurodegenerative disease characterized by the pathological accumulation of α-synuclein in the central nervous system and represents the second most prevalent cause of neurodegenerative dementia after Alzheimer’s disease (GALVIN, 2024; PRASAD et al., 2023). Clinically, it is manifested by cognitive fluctuations, recurrent visual hallucinations, spontaneous parkinsonism, and a high prevalence of sleep disorders, in addition to marked sensitivity to neuroleptics (WALKER; ZACCAI; QIZILBASH, 2015; ELDER et al., 2022). This study aimed to review the current evidence on the clinical and pharmacological management of DLB. This is a narrative literature review based on articles indexed in the PubMed database. The findings indicate that diagnosis is predominantly clinical, supported by biomarkers, and that treatment is essentially symptomatic, with emphasis on acetylcholinesterase inhibitors and multidisciplinary non-pharmacological interventions, which are fundamental to reducing iatrogenesis and improving quality of life (ALTY; LARNER, 2020; PARMERA et al., 2022).
References
Elder, G. J., & et al. (2022). Sleep disturbances in Lewy body dementia: A systematic review. International Journal of Geriatric Psychiatry, 37(10), 1–22.
Galvin, J. E. (2024). Dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn), 30(6), 1673–1698.
Gate, D., & et al. (2021). CD4+ T cells contribute to neurodegeneration in Lewy body dementia. Science, 374(6569), 868–874.
Hafiz, R., & et al. (2023). The latest advances in the diagnosis and treatment of dementia. Cureus, 15(12), Article e50522.
Hirofuji, S., & et al. (2023). Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system. Heliyon, 9(12), Article e21891. https://doi.org/10.1016/j.heliyon.2023.e21891
Johnson, J. C. S., & et al. (2021). Hearing and dementia: From ears to brain. Brain, 144(2), 391–401.
McKeith, I. G., & et al. (2017). Diagnosis and management of dementia with Lewy bodies. Neurology, 89(1), 88–100.
Parmera, J. B., & et al. (2022). Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: Recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dementia & Neuropsychologia, 16(3 Suppl. 1), 73–87. https://www.scielo.br/j/dn/a/HRDW5r6N5pLWtGBqBzxd87j/abstract/?lang=pt
Prasad, S., & et al. (2023). Recent advances in Lewy body dementia: A comprehensive review. Disease-a-Month, 69(5), Article 101441.
Walker, Z., Zaccai, J., & Qizilbash, N. (2015). Lewy body dementias. BMJ, 351, Article h5712.
Yeung, H. M., & et al. (2021). Development of neuroleptic malignant syndrome in a patient with Lewy body dementia after intramuscular administration of paliperidone. Case Reports in Neurological Medicine, 2021, 1–4. https://doi.org/10.1155/2021/8879333
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
